Shandong Suncadia Medicine Co., Ltd.
The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.
Type 2 Diabetes
HR20031 FDC
HR20031 FDC
HR20031 FDC
HR20031 FDC
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 40 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Study to Assess the Effect of Food on HR20031 Tablet in Healthy Subjects |
Actual Study Start Date : | January 31, 2023 |
Estimated Primary Completion Date : | March 11, 2023 |
Estimated Study Completion Date : | March 11, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: HR20031 FDC 10/100/1000 mg in the fast state |
Drug: HR20031 FDC |
Experimental: HR20031 FDC 10/100/1000 mg in the fed state |
Drug: HR20031 FDC |
Experimental: HR20031 FDC 5/50/750 mg*2 in the fast state |
Drug: HR20031 FDC |
Experimental: HR20031 FDC 5/50/750 mg*2 in the fed state |
Drug: HR20031 FDC |
Ages Eligible for Study: | 18 Years to 45 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008